Lymphocyte populations with different sensitivity to cyclosporin have different plasma membrane potentials

A. Aszalos, S. Damjanovich, P. Colombani, A. Hess

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Cyclosporin A (CsA), a clinically potent immunosuppressive agent, shows preferential biologic activity against certain lymphocyte subsets. To investigate this activity, we used flow cytometry to separate two distinct lymphocyte populations from unfractionated human peripheral blood lymphocytes, based on their different binding affinity for a biologically active fluorescent, dansylated cyclosporin (dans-CsA) derivative. The separate lymphocyte populations demonstrated different resting plasma membrane potentials. The two lymphocyte populations also had different levels of interleukin-2 (IL-2) receptors and shifted plasma membrane potential differently upon treatment with cyclosporin and lymphokine IL-2. The cell population that bound more dans-CsA contained the cells which possessed IL-2 receptors and responded to CsA and IL-2 with changes in membrane potential. The cell population that did not effectively bind dans-CsA lacked IL-2 receptors and did not respond to CsA or IL-2 with immediate membrane potential changes. Furthermore, stimulation studies of these separated two lymphocyte populations with phytohemagglutinin in the presence and absence of CsA revealed that only the population which binds a low level of dans-CsA shows a marked difference in membrane potential between the cells stimulated in the presence and absence of CsA. We concluded that ion flux changes caused by CsA affect the activation process of naive lymphocytes but not that of already stimulated ones. It can also be postulated that the ion flux changing property of CsA could constitute its primary or main mode of action.

Original languageEnglish
Pages (from-to)351-374
Number of pages24
JournalJournal of Medicine
Volume18
Issue number5-6
Publication statusPublished - 1987

Fingerprint

Membrane Potentials
Cyclosporine
Cell Membrane
Lymphocytes
Population
Interleukin-2 Receptors
Interleukin-2
Ions
Lymphokines
Lymphocyte Subsets
Phytohemagglutinins
Immunosuppressive Agents
Flow Cytometry

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lymphocyte populations with different sensitivity to cyclosporin have different plasma membrane potentials. / Aszalos, A.; Damjanovich, S.; Colombani, P.; Hess, A.

In: Journal of Medicine, Vol. 18, No. 5-6, 1987, p. 351-374.

Research output: Contribution to journalArticle

@article{f8f07d130b8d45c1a6a960dbfbffdb46,
title = "Lymphocyte populations with different sensitivity to cyclosporin have different plasma membrane potentials",
abstract = "Cyclosporin A (CsA), a clinically potent immunosuppressive agent, shows preferential biologic activity against certain lymphocyte subsets. To investigate this activity, we used flow cytometry to separate two distinct lymphocyte populations from unfractionated human peripheral blood lymphocytes, based on their different binding affinity for a biologically active fluorescent, dansylated cyclosporin (dans-CsA) derivative. The separate lymphocyte populations demonstrated different resting plasma membrane potentials. The two lymphocyte populations also had different levels of interleukin-2 (IL-2) receptors and shifted plasma membrane potential differently upon treatment with cyclosporin and lymphokine IL-2. The cell population that bound more dans-CsA contained the cells which possessed IL-2 receptors and responded to CsA and IL-2 with changes in membrane potential. The cell population that did not effectively bind dans-CsA lacked IL-2 receptors and did not respond to CsA or IL-2 with immediate membrane potential changes. Furthermore, stimulation studies of these separated two lymphocyte populations with phytohemagglutinin in the presence and absence of CsA revealed that only the population which binds a low level of dans-CsA shows a marked difference in membrane potential between the cells stimulated in the presence and absence of CsA. We concluded that ion flux changes caused by CsA affect the activation process of naive lymphocytes but not that of already stimulated ones. It can also be postulated that the ion flux changing property of CsA could constitute its primary or main mode of action.",
author = "A. Aszalos and S. Damjanovich and P. Colombani and A. Hess",
year = "1987",
language = "English",
volume = "18",
pages = "351--374",
journal = "Journal of Medicine",
issn = "0025-7850",
publisher = "S. Karger AG",
number = "5-6",

}

TY - JOUR

T1 - Lymphocyte populations with different sensitivity to cyclosporin have different plasma membrane potentials

AU - Aszalos, A.

AU - Damjanovich, S.

AU - Colombani, P.

AU - Hess, A.

PY - 1987

Y1 - 1987

N2 - Cyclosporin A (CsA), a clinically potent immunosuppressive agent, shows preferential biologic activity against certain lymphocyte subsets. To investigate this activity, we used flow cytometry to separate two distinct lymphocyte populations from unfractionated human peripheral blood lymphocytes, based on their different binding affinity for a biologically active fluorescent, dansylated cyclosporin (dans-CsA) derivative. The separate lymphocyte populations demonstrated different resting plasma membrane potentials. The two lymphocyte populations also had different levels of interleukin-2 (IL-2) receptors and shifted plasma membrane potential differently upon treatment with cyclosporin and lymphokine IL-2. The cell population that bound more dans-CsA contained the cells which possessed IL-2 receptors and responded to CsA and IL-2 with changes in membrane potential. The cell population that did not effectively bind dans-CsA lacked IL-2 receptors and did not respond to CsA or IL-2 with immediate membrane potential changes. Furthermore, stimulation studies of these separated two lymphocyte populations with phytohemagglutinin in the presence and absence of CsA revealed that only the population which binds a low level of dans-CsA shows a marked difference in membrane potential between the cells stimulated in the presence and absence of CsA. We concluded that ion flux changes caused by CsA affect the activation process of naive lymphocytes but not that of already stimulated ones. It can also be postulated that the ion flux changing property of CsA could constitute its primary or main mode of action.

AB - Cyclosporin A (CsA), a clinically potent immunosuppressive agent, shows preferential biologic activity against certain lymphocyte subsets. To investigate this activity, we used flow cytometry to separate two distinct lymphocyte populations from unfractionated human peripheral blood lymphocytes, based on their different binding affinity for a biologically active fluorescent, dansylated cyclosporin (dans-CsA) derivative. The separate lymphocyte populations demonstrated different resting plasma membrane potentials. The two lymphocyte populations also had different levels of interleukin-2 (IL-2) receptors and shifted plasma membrane potential differently upon treatment with cyclosporin and lymphokine IL-2. The cell population that bound more dans-CsA contained the cells which possessed IL-2 receptors and responded to CsA and IL-2 with changes in membrane potential. The cell population that did not effectively bind dans-CsA lacked IL-2 receptors and did not respond to CsA or IL-2 with immediate membrane potential changes. Furthermore, stimulation studies of these separated two lymphocyte populations with phytohemagglutinin in the presence and absence of CsA revealed that only the population which binds a low level of dans-CsA shows a marked difference in membrane potential between the cells stimulated in the presence and absence of CsA. We concluded that ion flux changes caused by CsA affect the activation process of naive lymphocytes but not that of already stimulated ones. It can also be postulated that the ion flux changing property of CsA could constitute its primary or main mode of action.

UR - http://www.scopus.com/inward/record.url?scp=0023574419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023574419&partnerID=8YFLogxK

M3 - Article

C2 - 3509802

AN - SCOPUS:0023574419

VL - 18

SP - 351

EP - 374

JO - Journal of Medicine

JF - Journal of Medicine

SN - 0025-7850

IS - 5-6

ER -